Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study
- PMID: 15447699
- DOI: 10.1111/j.1526-4610.2004.04172.x
Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study
Abstract
Objective: To compare the effectiveness of rizatriptan to other non-triptan medications in the relief of migraine headache in usual care settings.
Background: Although rizatriptan has been shown to provide effective relief of migraine symptoms in clinical trials, limited data exist directly comparing its effectiveness with non-triptan medications.
Methods: Migraineurs aged 18 to 55 who had been prescribed a new antimigraine drug (rizatriptan 10 mg or a selected class of non-triptan oral medications) were recruited to participate in the study through a national retail pharmacy chain. Participants completed a baseline questionnaire at the enrollment and reported their treatment experiences by filling out the treatment diary after using the newly prescribed medication. The treatment outcomes of patients receiving rizatriptan were compared with those receiving non-triptan medications. Logistic regression analysis was applied to test statistical significance with adjustment for potential confounding factors.
Results: Of the 728 patients who entered the study, 693 (95.2%) completed the treatment diary. Patients treated with rizatriptan (192) and non-triptans (501) reported the following outcomes, respectively--onset of headache relief within 30 minutes post-dose: 25% versus 18%; self-defined significant headache relief within 2 hours post-dose: 71% versus 54%; pain free or mild pain at 2 hours post-dose: 58% versus 47%; completely symptom-free within 2 hours of post-dose: 32% versus 20%; return to usual activities within 2 hours post-dose: 39% versus 35%; and satisfied with treatment: 67% versus 55% (P <.05 in all comparisons with exception of returning to usual activities).
Conclusion: Rizatriptan was significantly more effective than non-triptans in the relief of migraine headaches for patients obtaining prescribed migraine medications from a retail pharmacy. Additional studies at other usual care settings may be needed to confirm the findings.
Similar articles
-
Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.Clin Ther. 2006 Jun;28(6):872-80. doi: 10.1016/j.clinthera.2006.06.006. Clin Ther. 2006. PMID: 16860170 Clinical Trial.
-
Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting.Int J Clin Pract. 2003 Nov;57(9):761-8. Int J Clin Pract. 2003. PMID: 14686564 Clinical Trial.
-
Rizatriptan 10-mg wafer versus usual nontriptan therapy for migraine: analysis of return to function and patient preference.Headache. 2005 Oct;45(9):1140-50. doi: 10.1111/j.1526-4610.2005.00237.x. Headache. 2005. PMID: 16178944 Clinical Trial.
-
Rizatriptan in the treatment of migraine.Clin Ther. 1999 Nov;21(11):1823-36; discussion 1821. doi: 10.1016/S0149-2918(00)86731-4. Clin Ther. 1999. PMID: 10890255 Review.
-
Efficacy and tolerability of rizatriptan 10 mg compared with sumatriptan 100 mg: an evidence-based analysis.Expert Rev Neurother. 2010 Apr;10(4):499-506. doi: 10.1586/ern.10.24. Expert Rev Neurother. 2010. PMID: 20367203 Review.
Cited by
-
Treatment adherence in patients with headache: a systematic review.Headache. 2014 May;54(5):795-816. doi: 10.1111/head.12353. Epub 2014 Apr 17. Headache. 2014. PMID: 24750017 Free PMC article.
-
Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans.Int J Clin Pract. 2007 Jul;61(7):1091-111. doi: 10.1111/j.1742-1241.2007.01400.x. Epub 2007 May 30. Int J Clin Pract. 2007. PMID: 17537184 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical